Avlar BioVentures was a Cambridge, United Kingdom-based venture capital firm founded in 1999 by biotechnology entrepreneur Alan Goodman. See contact routes.
Avlar BioVentures was a Cambridge, United Kingdom-based venture capital firm founded in 1999 by biotechnology entrepreneur Alan Goodman and Daniel Roach to finance early-stage biotech companies. The firm’s investment thesis targeted seed and early-stage opportunities in biotechnology and healthcare across the UK and mainland Europe, focusing on therapeutics, diagnostics, medical devices, bioinformatics, and epigenetics. Initial checks ranged from £100,000 to £300,000 to launch companies, with follow-on funding available up to a total of £2 million, and the firm typically acted as an early-stage investor. Notable portfolio companies include Intercytex Group (the fund’s first investment), De Novo Pharmaceuticals, Purely Proteins Limited, CellCentric, and Crescendo Biologics. Avlar managed over €150 million across three funds, including Avlar BioVentures Fund I and Fund II, and completed 27 investments before its latest recorded activity in November 2011. The firm exited its investment in NXVISION and is now considered inactive, with its Fund II having been liquidated.
This profile is part of the StartupFundraising firm database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find comparable investors.
Investors like Avlar BioVentures · Full investor directory · Investor access · Company funding database